- Home
- UHS vs BMRN Comparison
UHS vs BMRN Comparison
Compare UHS & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHS
- BMRN
- Stock Information
- Founded
- UHS 1978
- BMRN 1996
- Country
- UHS United States
- BMRN United States
- Employees
- UHS N/A
- BMRN N/A
- Industry
- UHS Hospital/Nursing Management
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- UHS Health Care
- BMRN Health Care
- Exchange
- UHS Nasdaq
- BMRN Nasdaq
- Market Cap
- UHS 13.4B
- BMRN 10.5B
- IPO Year
- UHS N/A
- BMRN 1999
- Fundamental
- Price
- UHS $227.99
- BMRN $54.29
- Analyst Decision
- UHS Buy
- BMRN Buy
- Analyst Count
- UHS 13
- BMRN 19
- Target Price
- UHS $232.38
- BMRN $90.26
- AVG Volume (30 Days)
- UHS 692.0K
- BMRN 2.8M
- Earning Date
- UHS 10-27-2025
- BMRN 10-27-2025
- Dividend Yield
- UHS 0.35%
- BMRN N/A
- EPS Growth
- UHS 39.76
- BMRN 59.53
- EPS
- UHS 21.01
- BMRN 2.68
- Revenue
- UHS $16,992,503,000.00
- BMRN $3,094,001,000.00
- Revenue This Year
- UHS $10.41
- BMRN $13.32
- Revenue Next Year
- UHS $4.93
- BMRN $7.51
- P/E Ratio
- UHS $10.89
- BMRN $20.20
- Revenue Growth
- UHS 10.21
- BMRN 12.39
- 52 Week Low
- UHS $152.33
- BMRN $50.76
- 52 Week High
- UHS $231.37
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- UHS 64.61
- BMRN 53.35
- Support Level
- UHS $221.70
- BMRN $53.67
- Resistance Level
- UHS $231.37
- BMRN $55.34
- Average True Range (ATR)
- UHS 5.93
- BMRN 1.49
- MACD
- UHS -0.37
- BMRN 0.28
- Stochastic Oscillator
- UHS 83.86
- BMRN 78.60
About UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.